A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies (NCT05669430)
An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Who can join: Review the eligibility criteria below.
Location: The Angeles Clinic and Research Institute — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- The Angeles Clinic and Research Institute — Los Angeles, California
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Yale University — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute, LLC — Fort Myers, Florida
- Community Health Network, Inc. — Indianapolis, Indiana
- Massachusetts General Hospital — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center — Detroit, Michigan
- NYU Langone Health — New York, New York
- Oregon Health & Science University — Portland, Oregon
- Verdi Oncology Tennessee, Scri Oncology Partners — Nashville, Tennessee
- Oncology Consultants, P.A. — Houston, Texas
- The University of Texas M. D. Anderson Cancer Center — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (617) 256-2846
Email: clinicaltrials@gv20tx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.